FindTrial
Sign In

The Outcomes of Keratoprosthesis Implantation Combined with Autologous or Allogeneic Biomaterials in the Treatment of End-stage Ocular Surface Disorders

The Outcomes of Keratoprosthesis Implantation Combined with Autologous or Allogeneic Biomaterials in the Treatment of End-stage Ocular Surface Disorders

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022571
Enrollment
Unknown
Registered
2019-04-17
Start date
2018-07-01
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal diseases

Interventions

Case series:Boston Type II keratoprosthesis implantation combined with autologous or allogeneic biomaterials

Sponsors

Department of ophthalmology, Chinese People's Liberation Army General Hospital (PLAGH)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 58 Years

Inclusion criteria

Inclusion criteria: bilaterial blindness, severe dry eye, eyelid malfuction, SJS, OCP, and chemical burns

Exclusion criteria

Exclusion criteria: end-stage glaucoma, irreparable retinal detachment, phthisis bulbi, general anesthesia inability

Design outcomes

Primary

MeasureTime frame
visual acuity;—

Secondary

MeasureTime frame
corneal melting and aqueous leakage;—

Contacts

Public ContactYifei Huang

Department of ophthalmology, Chinese People's Liberation Army General Hospital (PLAGH)

301yk@sina.com+86 18600574957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026